Oragenics (OGEN) 10-Q/A14 Apr 232022 Q2 Quarterly report (amended)Financial data

Company Profile

Cover

Cover - shares	6 Months Ended
Cover - shares	Jun. 30, 2022	Aug. 08, 2022
Cover [Abstract]
Document Type	10-Q/A
Amendment Flag	true
Amendment Description	Oragenics Inc. (the “Company”) is filing this Amendment No. 1 on Form 10-Q/A (this “Amendment No. 1”) to amend its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2022, filed with the Securities and Exchange Commission (the “SEC”) on August 8, 2022 (the “Original Form 10-Q”).
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-32188
Entity Registrant Name	ORAGENICS, INC.
Entity Central Index Key	0001174940
Entity Tax Identification Number	59-3410522
Entity Incorporation, State or Country Code	FL
Entity Address, Address Line One	4902 Eisenhower Blvd.
Entity Address, Address Line Two	Suite 125
Entity Address, City or Town	Tampa
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33634
City Area Code	813
Local Phone Number	286-7900
Title of 12(b) Security	Common Stock
Trading Symbol	OGEN
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		116,394,806

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 17,867,483		$ 27,265,703
Other receivables			6,987
Prepaid expenses and other current assets	1,990,049		434,699
Total current assets	19,857,532		27,707,389
Property and equipment, net	109,780		45,708
Operating lease right-of-use assets	385,361		477,882
Total assets	20,352,673		28,230,979
Current liabilities:
Accounts payable and accrued expenses	1,279,598		947,574
Short-term notes payable			303,416
Operating lease liabilities	180,824		194,270
Total current liabilities	1,460,422		1,445,260
Long-term liabilities:
Operating lease liabilities	217,353		299,520
Total long-term liabilities	217,353		299,520
Shareholders’ equity:
Preferred stock, no par value; 50,000,000 shares authorized; 9,417,000 Series A shares, 6,600,000 Series B shares, issued and outstanding at June 30, 2022 and December 31, 2021, respectively	2,656,713		2,656,713
Common stock, $0.001 par value; 250,000,000 and 200,000,000 shares authorized at June 30, 2022 and December 31, 2021, respectively, 116,394,806 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively	116,395		116,395
Additional paid-in capital	195,356,454		194,987,219
Accumulated deficit	(179,454,664)		(171,274,128)
Total shareholders’ equity	18,674,898	$ 21,985,453	26,486,199	$ 32,733,400	$ 36,050,467	$ 16,844,595
Total liabilities and shareholders’ equity	$ 20,352,673		$ 28,230,979

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Preferred stock, no par value	$ 0	$ 0
Preferred stock, shares authorized	50,000,000	50,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	200,000,000
Common stock, shares issued	116,394,806	116,394,806
Common stock, shares outstanding	116,394,806	116,394,806
Series A Preferred Stock [Member]
Preferred stock, shares issued	9,417,000	9,417,000
Preferred stock, shares outstanding	9,417,000	9,417,000
Series B Preferred Stock [Member]
Preferred stock, shares issued	6,600,000	6,600,000
Preferred stock, shares outstanding	6,600,000	6,600,000

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended				4 Months Ended	6 Months Ended
Consolidated Statements of Operations (Unaudited) - USD ($)	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Grant revenue	$ 30,391				$ 30,391	$ 45,474
Operating expenses:
Research and development	2,590,032		2,467,575		2,590,032	5,883,693	5,728,479
General and administrative	1,044,334		1,370,393		1,044,334	2,375,883	3,346,969
Total operating expenses	3,634,366		3,837,968		3,634,366	8,259,576	9,075,448
Loss from operations	(3,603,975)		(3,837,968)		(3,603,975)	(8,214,102)	(9,075,448)
Other income (expense):
Interest income	15,369		24,254		15,369	27,275	44,287
Interest expense	(816)		(1,033)		(816)	(4,062)	(3,601)
Local business tax	(490)		(600)		(490)	(980)	(1,200)
Miscellaneous income	369				369	11,333	670
Total other income, net	14,432		22,621		14,432	33,566	40,156
Loss before income taxes	(3,589,543)		(3,815,347)		(3,589,543)	(8,180,536)	(9,035,292)
Income tax benefit
Net loss	$ (3,589,543)	$ (4,590,993)	$ (3,815,347)	$ (5,219,945)	$ (3,589,543)	$ (8,180,536)	$ (9,035,292)
Basic and diluted net loss per share	$ (0.03)		$ (0.03)		$ (0.03)	$ (0.07)	$ (0.08)
Shares used to compute basic and diluted net loss per share	116,394,806		115,864,162		116,394,806	116,394,806	109,357,191

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Preferred Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2020	$ 91,767	$ 7,174,854	$ 164,022,957	$ (154,444,983)	$ 16,844,595
Beginning balance, shares at Dec. 31, 2020	91,766,928	16,017,133.483
Compensation expense relating to option issuances			1,123,761		1,123,761
Net loss				(5,219,945)	(5,219,945)
Series C dividend		$ 1,117,531		(1,117,531)
Series C dividend, shares		33.016
Series C redemption		$ (5,635,672)			(5,635,672)
Series C redemption, shares		(166.499)
ATM offering - net of expenses	$ 21,399		26,654,993		26,676,392
ATM offering - net of expenses, shares	21,398,765
Issuance of common stock from warrant exercise	$ 2,472		2,258,864		2,261,336
Issuance of common stock from warrant exercise, shares	2,472,573
Ending balance, value at Mar. 31, 2021	$ 115,638	$ 2,656,713	194,060,575	(160,782,459)	36,050,467
Ending balance, shares at Mar. 31, 2021	115,638,266	16,017,000
Beginning balance, value at Dec. 31, 2020	$ 91,767	$ 7,174,854	164,022,957	(154,444,983)	16,844,595
Beginning balance, shares at Dec. 31, 2020	91,766,928	16,017,133.483
Net loss					(9,035,292)
Ending balance, value at Jun. 30, 2021	$ 116,195	$ 2,656,713	194,558,298	(164,597,806)	32,733,400
Ending balance, shares at Jun. 30, 2021	116,194,806	16,017,000
Beginning balance, value at Mar. 31, 2021	$ 115,638	$ 2,656,713	194,060,575	(160,782,459)	36,050,467
Beginning balance, shares at Mar. 31, 2021	115,638,266	16,017,000
Compensation expense relating to option issuances			231,140		231,140
Net loss				(3,815,347)	(3,815,347)
Issuance of common stock from option exercise	$ 557		266,583		267,140
Issuance of common stock from option exercise, shares	556,540
Ending balance, value at Jun. 30, 2021	$ 116,195	$ 2,656,713	194,558,298	(164,597,806)	32,733,400
Ending balance, shares at Jun. 30, 2021	116,194,806	16,017,000
Beginning balance, value at Dec. 31, 2021	$ 116,395	$ 2,656,713	194,987,219	(171,274,128)	26,486,199
Beginning balance, shares at Dec. 31, 2021	116,394,806	16,017,000
Compensation expense relating to option issuances			90,247		90,247
Net loss				(4,590,993)	(4,590,993)
Ending balance, value at Mar. 31, 2022	$ 116,395	$ 2,656,713	195,077,466	(175,865,121)	21,985,453
Ending balance, shares at Mar. 31, 2022	116,394,806	16,017,000
Beginning balance, value at Dec. 31, 2021	$ 116,395	$ 2,656,713	194,987,219	(171,274,128)	26,486,199
Beginning balance, shares at Dec. 31, 2021	116,394,806	16,017,000
Net loss					$ (8,180,536)
Issuance of common stock from option exercise, shares
Ending balance, value at Jun. 30, 2022	$ 116,395	$ 2,656,713	195,356,454	(179,454,664)	$ 18,674,898
Ending balance, shares at Jun. 30, 2022	116,394,806	16,017,000
Beginning balance, value at Mar. 31, 2022	$ 116,395	$ 2,656,713	195,077,466	(175,865,121)	21,985,453
Beginning balance, shares at Mar. 31, 2022	116,394,806	16,017,000
Compensation expense relating to option issuances			278,988		278,988
Net loss				(3,589,543)	(3,589,543)
Ending balance, value at Jun. 30, 2022	$ 116,395	$ 2,656,713	$ 195,356,454	$ (179,454,664)	$ 18,674,898
Ending balance, shares at Jun. 30, 2022	116,394,806	16,017,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
Consolidated Statements of Cash Flows (Unaudited) - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net loss	$ (8,180,536)	$ (9,035,292)
Depreciation and amortization	18,847	25,176
Gain on sale of property and equipment	(10,964)
Stock-based compensation expense	369,235	1,354,901
Changes in operating assets and liabilities:
Other receivables	6,987
Prepaid expenses and other current assets	(1,555,350)	256,189
Accounts payable and accrued expenses	332,024	993,251
Net cash used in operating activities	(9,019,757)	(6,405,775)
Cash flows from investing activities:
Proceeds from sale of property and equipment	12,000
Purchase of property and equipment	(87,047)
Net cash used in investing activities	(75,047)
Cash flows from financing activities:
Payments on short-term notes payable	(303,416)	(228,227)
Redemption of Series C Preferred stock		(5,635,672)
Proceeds from issuance of common stock for option exercise		267,140
Proceeds from issuance of common stock for warrant exercise		2,261,336
Net proceeds from issuance of common stock		26,676,392
Net cash provided by (used in) financing activities	(303,416)	23,340,969
Net increase (decrease) in cash and cash equivalents	(9,398,220)	16,935,194
Cash and cash equivalents at beginning of period	27,265,703	17,639,575
Cash and cash equivalents at end of period	17,867,483	34,574,769
Supplemental disclosure of cash flow information:
Interest paid	4,062	3,601
Non-cash investing and financing activities:
Stock dividend on Series C Preferred stock		$ 1,117,531

Organization

Organization	6 Months Ended
Organization	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	1. Organization Oragenics, Inc. (the “Company” or “we”) is focused on the development of the NT-CoV2-1 intranasal vaccine candidate to combat the novel Severe Acute Respiratory Syndrome coronavirus (“SARS-CoV-2”) and further development of effective treatments for novel antibiotics against infectious disease. 1A: Amendment To Previously Reported Quarterly Financial Statements The Management reviewed the terms and conditions of the contracts and the payments and concluded that during the three- and six-month period ended June 30, 2022 amounts were paid as part of a prepayment arrangement. Management reviewed Accounting Standards Codification Topic 730 Research and Development guidance related to recording initial upfront payments to vendors and determined that the unaudited consolidated financial statements originally reported for the three- and six- month periods ended June 30, 2022 classified research and development expense on the unaudited consolidated statement of operations that should be classified as prepaid expense on the Company’s unaudited consolidated balance sheet. The Company has restated its accounting for these prepaid research and development expenses and recorded them as prepaid assets on its unaudited consolidated balance sheet with changes to the amount of research and development expense recorded on its unaudited consolidated statement of operations for the three-and six- month periods ended June 30, 2022. As a result of these adjustments, net loss for the three and six months ended June 30, 2022 was reduced by approximately $ 0.4 million and $ 1.9 million respectively. The total assets reported for the six-month period ended June 30, 2022 increased by approximately $ 1.9 million. Total accumulated deficit for the six-month period ending June 30, 2022 was reduced by approximately $ 1.9 million. The Company has reported an amended net loss of $ 3.6 million and $ 8.2 million for the three and six months ended June 30, 2022 respectively; versus the previously reported net loss of approximately $ 4 million and $ 10 million . For the same six-month period ended June 30, 2022 the Company has also reported amended total assets of $ 20 million and accumulated deficit of $ 179 million versus $ 18 million and $ 181 million respectively. The following table summarizes the effect of the restatement on the Company’s unaudited consolidated financial statements for the three- and six- months ended June 30, 2022: Schedule of Effect of Restatement on Financial Statements Oragenics, Inc. Consolidated Balance Sheets June 30, 2022 As Previously Reported Adjustment As Restated (Unaudited) Assets Current assets: Cash and cash equivalents $ 17,867,483 $ 17,867,483 Other receivables - - Prepaid expenses and other current assets 102,498 1,887,551 1,990,049 Total current assets 17,969,981 19,857,532 Property and equipment, net 109,780 109,780 Operating lease right-of-use assets 385,361 385,361 Total assets $ 18,465,122 $ 20,352,673 Liabilities and Shareholders’ Equity Current liabilities: Accounts payable and accrued expenses $ 1,279,598 $ 1,279,598 Short-term notes payable - - Operating lease liabilities 180,824 180,824 Total current liabilities 1,460,422 1,460,422 Long-term liabilities: Operating lease liabilities 217,353 217,353 Total long-term liabilities 217,353 217,353 Shareholders’ equity: Preferred stock, no par value; 50,000,000 shares authorized; 9,417,000 Series A shares, 6,600,000 Series B shares, issued and outstanding at June 30, 2022 and December 31, 2021, respectively 2,656,713 2,656,713 Preferred stock, no par value; 50,000,000 shares authorized; 9,417,000 Series A shares, 6,600,000 Series B shares, issued and outstanding at June 30, 2022 and December 31, 2021, respectively 2,656,713 2,656,713 Common stock, $ 0.001 250,000,000 200,000,000 116,394,806 116,395 116,395 Additional paid-in capital 195,356,454 195,356,454 Accumulated deficit (181,342,215 ) 1,887,551 (179,454,664 ) Total shareholders’ equity 16,787,347 18,674,898 Total liabilities and shareholders’ equity $ 18,465,122 $ 20,352,673 Oragenics, Inc. Consolidated Statements of Operations (Unaudited) As Previously Reported Adjustment As Restated For the Three Months Ended June 30, 2022 As Previously Reported Adjustment As Restated Grant revenue $ 30,391 $ 30,391 Operating expenses: Research and development 3,033,182 (443,150 ) 2,590,032 General and administrative 1,044,334 1,044,334 Total operating expenses 4,077,516 3,634,366 Loss from operations (4,047,125 ) (3,603,975 ) Other income (expense): Interest income 15,369 15,369 Interest expense (816 ) (816 ) Local business tax (490 ) (490 ) Miscellaneous income 369 369 Total other income, net 14,432 14,432 Loss before income taxes (4,032,693 ) (3,589,543 ) Income tax benefit - - Net loss $ (4,032,693 ) $ (3,589,543 ) Basic and diluted net loss per share $ (0.03 ) $ (0.03 ) Shares used to compute basic and diluted net loss per share 116,394,806 116,394,806 Oragenics, Inc. Consolidated Statements of Operations (Unaudited) As Previously Reported Adjustment As Restated For the Six Months Ended June 30, 2022 As Previously Reported Adjustment As Restated Grant revenue $ 45,474 $ 45,474 Operating expenses: Research and development 7,771,244 (1,887,551 ) 5,883,693 General and administrative 2,375,883 2,375,883 Total operating expenses 10,147,127 8,259,576 Loss from operations (10,101,653 ) (8,214,102 ) Other income (expense): Interest income 27,275 27,275 Interest expense (4,062 ) (4,062 ) Local business tax (980 ) (980 ) Miscellaneous income 11,333 11,333 Total other income, net 33,566 33,566 Loss before income taxes (10,068,087 ) (8,180,536 ) Income tax benefit - - Net loss $ (10,068,087 ) $ (8,180,536 ) Basic and diluted net loss per share $ (0.09 ) $ (0.07 ) Shares used to compute basic and diluted net loss per share 116,394,806 116,394,806 Oragenics, Inc. Consolidated Statements of Cash Flows (Unaudited) As Previously Reported Adjustment As Restated For the Six Months Ended June 30, 2022 As Previously Reported Adjustment As Restated Cash flows from operating activities: Net loss $ (10,068,087 ) 1,887,551 $ (8,180,536 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 18,847 18,847 Gain on sale of property and equipment (10,964 ) (10,964 ) Stock-based compensation expense 369,235 369,235 Changes in operating assets and liabilities: - Other receivables 6,987 6,987 Prepaid expenses and other current assets 332,201 (1,887,551 ) (1,555,350 ) Accounts payable and accrued expenses 332,024 332,024 Net cash used in operating activities (9,019,757 ) (9,019,757 ) Cash flows from investing activities: Proceeds from sale of property and equipment 12,000 12,000 Purchase of property and equipment (87,047 ) (87,047 ) Net cash used in investing activities (75,047 ) (75,047 ) Cash flows from financing activities: Payments on short-term notes payable (303,416 ) (303,416 ) Redemption of Series C Preferred stock - - Proceeds from issuance of common stock for option exercise - - Proceeds from issuance of common stock for warrant exercise - - Net proceeds from issuance of common stock - - Net cash provided by (used in) financing activities (303,416 ) (303,416 ) Net increase (decrease) in cash and cash equivalents (9,398,220 (9,398,220 ) Cash and cash equivalents at beginning of period 27,265,703 - 27,265,703 Cash and cash equivalents at end of period $ 17,867,483 $ 17,867,483 Supplemental disclosure of cash flow information: Interest paid $ 4,062 $ 4,062 Non-cash investing and financing activities: - - Stock dividend on Series C Preferred stock $ - $ -

Basis of Presentation, As Resta

Basis of Presentation, As Restated	6 Months Ended
Basis of Presentation, As Restated	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation, As Restated	2. Basis of Presentation, As Restated The accompanying unaudited interim consolidated financial statements as of June 30, 2022 and December 31, 2021 (audited) and three and six months ended June 30, 2022 and 2021, have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) for interim consolidated financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by US GAAP for complete consolidated financial statements. In the opinion of management, the accompanying consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the financial condition, results of operations and cash flows for the periods presented. The results of operations for the interim period ended June 30, 2022, are not necessarily indicative of the results of operations that may be expected for the year ended December 31, 2022, or any future period. These consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2021, which are included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 24, 2022. The Company has incurred recurring losses and negative cash flows from operations since inception. To date, the Company has not generated significant revenues from operations. The Company incurred a net loss of $ 8,180,536 9,019,757 179,454,664 The Company expects to incur substantial expenditures to further develop its technologies. The Company believes the working capital at June 30, 2022 will be sufficient to meet the business objectives as presently structured through the fourth quarter of 2022. As such, there is substantial doubt that we can continue as a going concern beyond that date. The Company’s ability to continue operations after its current cash resources are exhausted depends on its ability to obtain additional financing or achieve profitable operations, as to which no assurances can be given. Cash requirements may vary materially from those now planned because of changes in the Company’s focus and direction of its research and development programs, competitive and technical advances, or other developments. Additional financing will be required to continue operations after the Company exhausts its current cash resources and to continue its long-term plans for clinical trials and new product development. There can be no assurance that any such financing can be realized by the Company, or if realized, what the terms thereof may be, or that any amount that the Company is able to raise will be adequate to support the Company’s working capital requirements until it achieves profitable operations. The Company intends to seek additional funding through sublicensing arrangements, joint venturing or partnering, sales of rights to technology, government grants and public or private financings. The Company’s future success depends on its ability to raise capital and ultimately generate revenue and attain profitability. The Company cannot be certain that additional capital, whether through selling additional debt or equity securities or obtaining a line of credit or other loan, will be available to it or, if available, will be on terms acceptable to the Company. If the Company issues additional securities to raise funds, these securities may have rights, preferences, or privileges senior to those of its common stock, and the Company’s current shareholders may experience dilution. If the Company is unable to obtain funds when needed or on acceptable terms, the Company may be required to curtail its current development programs, cut operating costs and forego future development and other opportunities.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
Significant Accounting Policies	Jun. 30, 2022
Accounting Policies [Abstract]
Significant Accounting Policies	3. Significant Accounting Policies Basis of Consolidation The consolidated financial statements include the accounts of Oragenics, Inc. and our wholly-owned subsidiary Noachis Terra, Inc.(“NTI”). All intercompany balances and transactions have been eliminated. New Accounting Standards There are no additional accounting pronouncements issued or effective during the three and six months ended June 30, 2022, that have had, or are expected to have, a material impact on our consolidated financial statements. Use of Estimates The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. The principal area of estimation reflected in the consolidated financial statements is stock-based compensation. Stock-Based Payment Arrangements Generally, all forms of stock-based payments, including stock option grants, and warrants are measured at their fair value on the awards’ grant date using a Black-Scholes pricing model. Stock-based compensation awards issued to non-employees for services rendered are recorded at the fair value of the stock-based payment. The expense resulting from stock-based payments are recorded in research and development expense or general and administrative expense in the consolidated statement of operations, depending on the nature of the services provided. Stock-based payment expense is recorded over the requisite service period in which the grantee provides services to us. To the extent the stock option grants, or warrants do not vest at the grant date they are subject to forfeiture. Stock-Based Compensation US GAAP requires all stock-based payments to employees, including grants of employee stock options, to be recognized in the consolidated financial statements based on their fair values as of the grant date. Stock-based compensation expense is recorded over the requisite service period in which the grantee provides services to us, to the extent the options do not vest at the grant date and are subject to forfeiture. For performance-based awards that do not include market-based conditions, we record share-based compensation expense only when the performance-based milestone is deemed probable of achievement. We utilize both quantitative and qualitative criteria to judge whether milestones are probable of achievement. For awards with market-based performance conditions, we recognize the grant-date fair value of the award over the derived service period regardless of whether the underlying performance condition is met. In connection with adopting ASU 2016-09, the Company made an accounting policy election to account for forfeitures in compensation expense as they occur. Warrants The Company used the Black Scholes Option Pricing Model in calculating the relative fair value of any warrants that have been issued. Net Loss Per Share During all periods presented, the Company had securities outstanding that could potentially dilute basic earnings per share in the future but were excluded from the computation of diluted net loss per share, as their effect would have been antidilutive because the Company reported a net loss for all periods presented. Basic and diluted net loss per share amounts are the same for the periods presented. Net loss per share is computed using the weighted average number of shares of common stock outstanding. Concentrations Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents. As of June 30, 2022, the uninsured portion of this balance was $ 17,617,483 27,015,703 Grant Revenue Grant revenues are derived from a small business innovation research grant in the amount of $ 250,000

Stock-based Compensation

Stock-based Compensation	6 Months Ended
Stock-based Compensation	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock-based Compensation	4. Stock-based Compensation The Company recognized stock-based compensation on all employee and non-employee awards as follows: Schedule of Stock Based Compensation Expenses Recognized For the Three Months Ended June 30, 2022 For the Three Months Ended June 30, 2021 For the Six Months Ended June 30, 2022 For the Six Months Ended June 30, 2021 Research and development $ 26,399 $ 48,761 $ 65,854 $ 79,688 General and administrative 252,589 182,379 303,381 1,275,213 Total Stock-based compensation $ 278,988 $ 231,140 $ 369,235 $ 1,354,901 The following table summarizes the stock option activity during the six months ended June 30, 2022: Summary of Stock Option Activity Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (In Years) Aggregate Intrinsic Value (1) Outstanding at December 31, 2021 6,724,402 $ 0.95 7.99 $ 2,773 Granted 1,382,500 0.32 — $ — Exercised — — — $ — Expired (4,500 ) 12.00 Forfeited (726,998 ) 0.94 — $ — Outstanding at June 30, 2022 7,375,404 $ 0.83 8.06 $ 72,050 Exercisable at June 30, 2022 5,952,900 $ 0.89 7.74 $ 36,300 (1) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock option awards and the closing market price of our common stock as of December 31, 2021 and June, 2022, respectively. Total unrecognized compensation cost related to unvested stock options was $ 436,162 two years On February 25, 2022, the Company held its reconvened 2020 Annual Meeting. At the reconvened 2020Annual Meeting, the shareholders of the Company approved and ratified the Company’s 2021 Equity Incentive Plan (the “2021 Plan”) which is a successor to the Company’s 2012 Equity Incentive Plan (the “2012 Plan”).The 2021 Plan provides the aggregate number of shares of Common Stock that may be issued under the 2021 Plan will not exceed the sum of (i) 10,000,000 As of June 30, 2022, 9,877,306 Each executive officer and non-employee director receiving equity-based awards is subject to a minimum dollar value stock ownership holding requirement with respect to the awards received as well as all prior equity awards under the Plan which requirements are intended to align the ability to sell shares with the performance of the Company’s stock price. The executive officer recipients each have a minimum dollar value stock ownership holding requirement threshold equal to two times (2x) their then base salaries below which dollar threshold they would be precluded from selling any shares of Company stock obtained from the Company under its Plan. Also, the non-employee directors are each subject to a minimum dollar value stock ownership holding requirement threshold equal to six times the annual Board retainer ($270,000)

Warrants

Warrants	6 Months Ended
Warrants	Jun. 30, 2022
Warrants
Warrants	5. Warrants During the three months ended March 31, 2021, the Company issued an additional 2,472,573 360,000 1.00 2,112,573 0.90 2,261,336 A summary of warrant activity for the year ended December 31, 2021 and the six months ended June 30, 2022 is as follows: Schedule of Warrants Activity Warrants Weighted Average Price Balance - December 31, 2020 20,513,145 $ 1.36 Granted — — Exercised (2,472,573 ) 0.91 Expired — — Balance - December 31, 2021 18,040,572 1.42 Granted — — Exercised — — Expired — — Balance - June 30, 2022 18,040,572 $ 1.42 The warrants outstanding as of June 30, 2022 are as follows: Schedule of Warrants Outstanding Exercise Price Warrants Outstanding Expiration Date $ 3.10 48,387 9/19/2022 $ 2.00 900,000 4/10/2023 $ 3.10 462,106 5/10/2024 $ 3.10 602,414 7/25/2024 $ 3.10 1,064,518 11/8/2024 $ 1.00 3,174,500 7/17/2025 $ 0.90 2,588,647 3/25/2024 $ 1.25 9,200,000 5/1/2025 18,040,572 All outstanding warrants are classified as equity on the Company’s Consolidated Balance Sheets.

Prepaids, As Restated

Prepaids, As Restated	6 Months Ended
Prepaids, As Restated	Jun. 30, 2022
Prepaids As Restated
Prepaids, As Restated	6. Prepaids, As Restated As of June 30, 2022 and December 31, 2021, the Company had $ 1,990,049 and $ 434,699 , respectively, in prepaid expense and other current assets. The balance on June 30, 2022 consists of approximately $ 1.9 0.08 0.02 Schedule of Prepaids June 30, December 31, 2022 2021 Prepaid Expense 1,972,109 416,759 Deposits 17,940 17,940 Total 1,990,049 434,699

Short-Term Notes Payable

Short-Term Notes Payable	6 Months Ended
Short-Term Notes Payable	Jun. 30, 2022
Debt Disclosure [Abstract]
Short-Term Notes Payable	7. Short-Term Notes Payable As of June 30, 2022 and December 31, 2021, the Company had $— and $ 303,416 Products Liability Insurance The product liability insurance policy has been renewed in subsequent periods without premium financing. Directors’ and Officers’ Insurance On July 24, 2021, the Company entered into a short-term note payable for $ 600,169 5.34 10-month May 16, 2022 On July 24, 2020, the Company entered into a short-term note payable for $ 413,784 5.39 11-month June 28, 2021

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies Additional Consideration-NTI Acquisition In connection with the Company’s acquisition of NTI in May of 2020, the Company is obligated to pay the former sole shareholder of NTI contingent consideration based upon the exercise of certain of the Company’s outstanding warrants as follows: (i) twenty percent ( 20 0.75 0.90 45 1.00 The Company’s previously issued warrants carrying an exercise price of $0.75 have expired by their terms. As a result, no additional consideration will be due to the former sole shareholder of NTI relating to these warrants. During the three months ended March 31, 2021, 2,472,573 360,000 1.00 2,112,573 0.90 As a result of the warrant exercises in 2021, the Company paid $ 542,263 During the three months ended June 30, 2022, no warrants were exercised that resulted in the payment of additional consideration to the sole former shareholder of NTI. NIH License Through NTI, the Company is a party to a Patent License and Biological Materials License Agreement (the “NIH License Agreement” or “NIH License”), dated March 23, 2020, with the United States Department of Health and Human Services (the “HHS”), as represented by the National Institute of Allergy and Infectious Diseases (“NIAID”), an Institute within the National Institutes of Health (“NIH”). Under the terms of the NIH License Agreement, we hold a nonexclusive, worldwide license to certain specified patent rights (including patent applications, provisional patent applications and Patent Cooperation Treaty (“PCT”) patent applications) and biological materials relating to the use of pre-fusion coronavirus spike proteins to exploit products (“Licensed Products”) and practice processes (“Licensed Processes”) that are covered by the licensed patent rights and biological materials for the purpose of developing and commercializing a vaccine product candidate for SARS-CoV-2. Under the terms of the NIH License Agreement, the NIAID is entitled to receive a non-creditable, nonrefundable upfront license issue royalty of $ 30,000 11,739 The NIH License Agreement will expire upon (a) twenty ( 20 NRC License On July 26, 2021, the Company entered into a non-exclusive Technology License Agreement (the “NRC License Agreement”) with the National Research Council of Canada (“NRC”) pursuant to which the NRC grants to the Company a license to use NRC’s inventions, patents, trade secrets, know-how, copyright, biological material, designs, and/or technical information created by or on behalf of the NRC (the “NRC Technologies”) relating to the derivatives of CHO 2353 TM ”) As consideration for the grant of the license, the Company will pay to the NRC an annual (low five digits) license fee, with the initial portion of the fee covering the first three years of the license. Additionally, we will pay certain milestone payments (a) upon transfer of each Stable Cell listed in the Agreement and (b) with regard to each of the first three Products, (i) upon submission of the Investigational New Drug application (IND) related thereto, (ii) upon dosing the first patient in a Phase 1 or Phase 2 clinical trial, (iii) upon dosing the first patient in a Phase 3 clinical trial and (iv) upon first regulatory approval. Milestone payments range from the low five digits to high six digits. In addition, Oragenics will pay a low single-digit royalty to the NRC for the sale of Products, based on sales revenue, commencing after the first commercial sale. Pursuant to the NRC License Agreement, the NRC is required to bear the responsibility and pay the costs to obtain and maintain patents related to the NRC Technologies in the U.S., Canada, Brazil, European Union, Japan, South Korea, Singapore, Australia, China, and India, and the NRC shall use reasonable efforts to obtain and maintain those patents. Additional countries may be requested by us, in which event, the NRC will file and maintain such patents, at our expense. Pursuant to the NRC License Agreement, we are required to indemnify and hold the NRC and its employees and agents harmless from and against all liability and damages in connection with or arising out of all claims, demands, losses, damages, costs including solicitor and client costs, actions, suits or proceedings brought by any third party that are in any manner based upon, arising out of, related to, occasioned by, or attributable to the manufacturing, distribution, shipment, offering for sale, sale, or use of Products, services based on the NRC Technologies and product liability and infringement of intellectual property rights other than copyright, if any, licensed under the NRC License Agreement. Unless terminated earlier, the NRC License Agreement will terminate twenty (20) years from the effective date of the NRC License Agreement. Either party may terminate the NRC License Agreement, by giving written notice to the other party, if the other party defaults or is in breach of the NRC License Agreement, provided that if the defaulting party cures the breach within 60 days after the notice is given, the NRC License Agreement shall continue in full force and effect. The NRC may terminate the NRC License Agreement if the Company becomes bankrupt, or insolvent, or has a receiver appointed to continue its operations, or passes a resolution for winding up. The NRC License Agreement contains customary confidentiality obligations. In addition, in connection with the initiative to develop its vaccine, we also previously entered into a material transfer agreement with the NRC for SARS-CoV-2 trimeric spike protein Wuhan variant and SARS-CoV-2 trimeric spike protein South African variant to move forward with pre-clinical testing. Leases Lab Facility-Alachua. 12,870 13,338 Corporate Office – Tampa. 2,207 The lease period for the office space is for thirty-six months commencing on March 1, 2017. 4,138 4,392 February 29, 2020 the Company entered into an amendment for the Tampa facility for a term of three years beginning in March of 2020. 4,524 4,800 Supplemental balance sheet information related to leases is as follows: Schedule of Supplemental Balance Sheet Information Related to Leases June 30, 2022 December 31, 2021 Weighted Average Remaining Lease Term In Years Operating leases 1.95 2.45 Weighted Average Discount Rate Operating leases 5.69 % 5.70 % Maturities of operating lease liabilities are as follows: Schedule of Maturities of Operating Lease Liabilities Year ended December 31: 2022 $ 108,829 2023 169,656 2024 146,718 Total $ 425,203 Less: Imputed interest (27,026 ) Present value of lease liabilities $ 398,177 The cost component of operating leases is as follows: Schedule of Cost Component of Operating Leases For the Six Months Ended June 30, 2022 For the Six Months Ended June 30, 2021 Operating lease cost $ 114,259 $ 114,002 Short-term lease cost 1,965 782 Total lease cost $ 116,224 $ 114,784 Supplemental cash flow information related to operating leases is as follows: Schedule of Supplemental Cash Flow Information Related to Operating Leases For the Six Months Ended June 30, 2022 For the Six Months Ended June 30, 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 117,350 $ 113,454

Shareholders_ Equity

Shareholders’ Equity	6 Months Ended
Shareholders’ Equity	Jun. 30, 2022
Equity [Abstract]
Shareholders’ Equity	9. Shareholders’ Equity Common Stock The Company’s Board of Directors and the Company’s shareholders, at its reconvened 2020 Annual Meeting on February 25, 2022, approved an amendment to our Amended and Restated Articles of Incorporation to (i) increase the number of authorized shares of common stock from 200,000,000 250,000,000 During the three and six months ended June 30, 2022, the Company issued no shares of common stock . During the three months ended March 31, 2021, the Company issued an aggregate of 23,871,338 21,398,765 27.8 2,472,573 2.3 Preferred Stock Series C Non-Voting, Non-Convertible, Preferred Stock Dividend and Redemption During the three months ended March 31, 2021, the Company provided a notice of redemption, to the holder of the Company’s Series C Preferred Stock to redeem all outstanding Series C Preferred Stock (which included the dividend of 26.697 5.6

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	6 Months Ended
Significant Accounting Policies (Policies)	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Consolidation	Basis of Consolidation The consolidated financial statements include the accounts of Oragenics, Inc. and our wholly-owned subsidiary Noachis Terra, Inc.(“NTI”). All intercompany balances and transactions have been eliminated.
New Accounting Standards	New Accounting Standards There are no additional accounting pronouncements issued or effective during the three and six months ended June 30, 2022, that have had, or are expected to have, a material impact on our consolidated financial statements.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. The principal area of estimation reflected in the consolidated financial statements is stock-based compensation.
Stock-Based Payment Arrangements	Stock-Based Payment Arrangements Generally, all forms of stock-based payments, including stock option grants, and warrants are measured at their fair value on the awards’ grant date using a Black-Scholes pricing model. Stock-based compensation awards issued to non-employees for services rendered are recorded at the fair value of the stock-based payment. The expense resulting from stock-based payments are recorded in research and development expense or general and administrative expense in the consolidated statement of operations, depending on the nature of the services provided. Stock-based payment expense is recorded over the requisite service period in which the grantee provides services to us. To the extent the stock option grants, or warrants do not vest at the grant date they are subject to forfeiture.
Stock-Based Compensation	Stock-Based Compensation US GAAP requires all stock-based payments to employees, including grants of employee stock options, to be recognized in the consolidated financial statements based on their fair values as of the grant date. Stock-based compensation expense is recorded over the requisite service period in which the grantee provides services to us, to the extent the options do not vest at the grant date and are subject to forfeiture. For performance-based awards that do not include market-based conditions, we record share-based compensation expense only when the performance-based milestone is deemed probable of achievement. We utilize both quantitative and qualitative criteria to judge whether milestones are probable of achievement. For awards with market-based performance conditions, we recognize the grant-date fair value of the award over the derived service period regardless of whether the underlying performance condition is met. In connection with adopting ASU 2016-09, the Company made an accounting policy election to account for forfeitures in compensation expense as they occur.
Warrants	Warrants The Company used the Black Scholes Option Pricing Model in calculating the relative fair value of any warrants that have been issued.
Net Loss Per Share	Net Loss Per Share During all periods presented, the Company had securities outstanding that could potentially dilute basic earnings per share in the future but were excluded from the computation of diluted net loss per share, as their effect would have been antidilutive because the Company reported a net loss for all periods presented. Basic and diluted net loss per share amounts are the same for the periods presented. Net loss per share is computed using the weighted average number of shares of common stock outstanding.
Concentrations	Concentrations Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents. As of June 30, 2022, the uninsured portion of this balance was $ 17,617,483 27,015,703
Grant Revenue	Grant Revenue Grant revenues are derived from a small business innovation research grant in the amount of $ 250,000

Organization (Tables)

Organization (Tables)	6 Months Ended
Organization (Tables)	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Effect of Restatement on Financial Statements	The following table summarizes the effect of the restatement on the Company’s unaudited consolidated financial statements for the three- and six- months ended June 30, 2022: Schedule of Effect of Restatement on Financial Statements Oragenics, Inc. Consolidated Balance Sheets June 30, 2022 As Previously Reported Adjustment As Restated (Unaudited) Assets Current assets: Cash and cash equivalents $ 17,867,483 $ 17,867,483 Other receivables - - Prepaid expenses and other current assets 102,498 1,887,551 1,990,049 Total current assets 17,969,981 19,857,532 Property and equipment, net 109,780 109,780 Operating lease right-of-use assets 385,361 385,361 Total assets $ 18,465,122 $ 20,352,673 Liabilities and Shareholders’ Equity Current liabilities: Accounts payable and accrued expenses $ 1,279,598 $ 1,279,598 Short-term notes payable - - Operating lease liabilities 180,824 180,824 Total current liabilities 1,460,422 1,460,422 Long-term liabilities: Operating lease liabilities 217,353 217,353 Total long-term liabilities 217,353 217,353 Shareholders’ equity: Preferred stock, no par value; 50,000,000 shares authorized; 9,417,000 Series A shares, 6,600,000 Series B shares, issued and outstanding at June 30, 2022 and December 31, 2021, respectively 2,656,713 2,656,713 Preferred stock, no par value; 50,000,000 shares authorized; 9,417,000 Series A shares, 6,600,000 Series B shares, issued and outstanding at June 30, 2022 and December 31, 2021, respectively 2,656,713 2,656,713 Common stock, $ 0.001 250,000,000 200,000,000 116,394,806 116,395 116,395 Additional paid-in capital 195,356,454 195,356,454 Accumulated deficit (181,342,215 ) 1,887,551 (179,454,664 ) Total shareholders’ equity 16,787,347 18,674,898 Total liabilities and shareholders’ equity $ 18,465,122 $ 20,352,673 Oragenics, Inc. Consolidated Statements of Operations (Unaudited) As Previously Reported Adjustment As Restated For the Three Months Ended June 30, 2022 As Previously Reported Adjustment As Restated Grant revenue $ 30,391 $ 30,391 Operating expenses: Research and development 3,033,182 (443,150 ) 2,590,032 General and administrative 1,044,334 1,044,334 Total operating expenses 4,077,516 3,634,366 Loss from operations (4,047,125 ) (3,603,975 ) Other income (expense): Interest income 15,369 15,369 Interest expense (816 ) (816 ) Local business tax (490 ) (490 ) Miscellaneous income 369 369 Total other income, net 14,432 14,432 Loss before income taxes (4,032,693 ) (3,589,543 ) Income tax benefit - - Net loss $ (4,032,693 ) $ (3,589,543 ) Basic and diluted net loss per share $ (0.03 ) $ (0.03 ) Shares used to compute basic and diluted net loss per share 116,394,806 116,394,806 Oragenics, Inc. Consolidated Statements of Operations (Unaudited) As Previously Reported Adjustment As Restated For the Six Months Ended June 30, 2022 As Previously Reported Adjustment As Restated Grant revenue $ 45,474 $ 45,474 Operating expenses: Research and development 7,771,244 (1,887,551 ) 5,883,693 General and administrative 2,375,883 2,375,883 Total operating expenses 10,147,127 8,259,576 Loss from operations (10,101,653 ) (8,214,102 ) Other income (expense): Interest income 27,275 27,275 Interest expense (4,062 ) (4,062 ) Local business tax (980 ) (980 ) Miscellaneous income 11,333 11,333 Total other income, net 33,566 33,566 Loss before income taxes (10,068,087 ) (8,180,536 ) Income tax benefit - - Net loss $ (10,068,087 ) $ (8,180,536 ) Basic and diluted net loss per share $ (0.09 ) $ (0.07 ) Shares used to compute basic and diluted net loss per share 116,394,806 116,394,806 Oragenics, Inc. Consolidated Statements of Cash Flows (Unaudited) As Previously Reported Adjustment As Restated For the Six Months Ended June 30, 2022 As Previously Reported Adjustment As Restated Cash flows from operating activities: Net loss $ (10,068,087 ) 1,887,551 $ (8,180,536 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 18,847 18,847 Gain on sale of property and equipment (10,964 ) (10,964 ) Stock-based compensation expense 369,235 369,235 Changes in operating assets and liabilities: - Other receivables 6,987 6,987 Prepaid expenses and other current assets 332,201 (1,887,551 ) (1,555,350 ) Accounts payable and accrued expenses 332,024 332,024 Net cash used in operating activities (9,019,757 ) (9,019,757 ) Cash flows from investing activities: Proceeds from sale of property and equipment 12,000 12,000 Purchase of property and equipment (87,047 ) (87,047 ) Net cash used in investing activities (75,047 ) (75,047 ) Cash flows from financing activities: Payments on short-term notes payable (303,416 ) (303,416 ) Redemption of Series C Preferred stock - - Proceeds from issuance of common stock for option exercise - - Proceeds from issuance of common stock for warrant exercise - - Net proceeds from issuance of common stock - - Net cash provided by (used in) financing activities (303,416 ) (303,416 ) Net increase (decrease) in cash and cash equivalents (9,398,220 (9,398,220 ) Cash and cash equivalents at beginning of period 27,265,703 - 27,265,703 Cash and cash equivalents at end of period $ 17,867,483 $ 17,867,483 Supplemental disclosure of cash flow information: Interest paid $ 4,062 $ 4,062 Non-cash investing and financing activities: - - Stock dividend on Series C Preferred stock $ - $ -

Stock-based Compensation (Table

Stock-based Compensation (Tables)	6 Months Ended
Stock-based Compensation (Tables)	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Stock Based Compensation Expenses Recognized	The Company recognized stock-based compensation on all employee and non-employee awards as follows: Schedule of Stock Based Compensation Expenses Recognized For the Three Months Ended June 30, 2022 For the Three Months Ended June 30, 2021 For the Six Months Ended June 30, 2022 For the Six Months Ended June 30, 2021 Research and development $ 26,399 $ 48,761 $ 65,854 $ 79,688 General and administrative 252,589 182,379 303,381 1,275,213 Total Stock-based compensation $ 278,988 $ 231,140 $ 369,235 $ 1,354,901
Summary of Stock Option Activity	The following table summarizes the stock option activity during the six months ended June 30, 2022: Summary of Stock Option Activity Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (In Years) Aggregate Intrinsic Value (1) Outstanding at December 31, 2021 6,724,402 $ 0.95 7.99 $ 2,773 Granted 1,382,500 0.32 — $ — Exercised — — — $ — Expired (4,500 ) 12.00 Forfeited (726,998 ) 0.94 — $ — Outstanding at June 30, 2022 7,375,404 $ 0.83 8.06 $ 72,050 Exercisable at June 30, 2022 5,952,900 $ 0.89 7.74 $ 36,300 (1) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock option awards and the closing market price of our common stock as of December 31, 2021 and June, 2022, respectively.

Warrants (Tables)

Warrants (Tables)	6 Months Ended
Warrants (Tables)	Jun. 30, 2022
Warrants
Schedule of Warrants Activity	A summary of warrant activity for the year ended December 31, 2021 and the six months ended June 30, 2022 is as follows: Schedule of Warrants Activity Warrants Weighted Average Price Balance - December 31, 2020 20,513,145 $ 1.36 Granted — — Exercised (2,472,573 ) 0.91 Expired — — Balance - December 31, 2021 18,040,572 1.42 Granted — — Exercised — — Expired — — Balance - June 30, 2022 18,040,572 $ 1.42
Schedule of Warrants Outstanding	The warrants outstanding as of June 30, 2022 are as follows: Schedule of Warrants Outstanding Exercise Price Warrants Outstanding Expiration Date $ 3.10 48,387 9/19/2022 $ 2.00 900,000 4/10/2023 $ 3.10 462,106 5/10/2024 $ 3.10 602,414 7/25/2024 $ 3.10 1,064,518 11/8/2024 $ 1.00 3,174,500 7/17/2025 $ 0.90 2,588,647 3/25/2024 $ 1.25 9,200,000 5/1/2025 18,040,572

Prepaids, As Restated (Tables)

Prepaids, As Restated (Tables)	6 Months Ended
Prepaids, As Restated (Tables)	Jun. 30, 2022
Prepaids As Restated
Schedule of Prepaids	Schedule of Prepaids June 30, December 31, 2022 2021 Prepaid Expense 1,972,109 416,759 Deposits 17,940 17,940 Total 1,990,049 434,699

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
Commitments and Contingencies (Tables)	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of Supplemental Balance Sheet Information Related to Leases	Supplemental balance sheet information related to leases is as follows: Schedule of Supplemental Balance Sheet Information Related to Leases June 30, 2022 December 31, 2021 Weighted Average Remaining Lease Term In Years Operating leases 1.95 2.45 Weighted Average Discount Rate Operating leases 5.69 % 5.70 %
Schedule of Maturities of Operating Lease Liabilities	Maturities of operating lease liabilities are as follows: Schedule of Maturities of Operating Lease Liabilities Year ended December 31: 2022 $ 108,829 2023 169,656 2024 146,718 Total $ 425,203 Less: Imputed interest (27,026 ) Present value of lease liabilities $ 398,177
Schedule of Cost Component of Operating Leases	The cost component of operating leases is as follows: Schedule of Cost Component of Operating Leases For the Six Months Ended June 30, 2022 For the Six Months Ended June 30, 2021 Operating lease cost $ 114,259 $ 114,002 Short-term lease cost 1,965 782 Total lease cost $ 116,224 $ 114,784
Schedule of Supplemental Cash Flow Information Related to Operating Leases	Supplemental cash flow information related to operating leases is as follows: Schedule of Supplemental Cash Flow Information Related to Operating Leases For the Six Months Ended June 30, 2022 For the Six Months Ended June 30, 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 117,350 $ 113,454

Schedule of Effect of Restateme

Schedule of Effect of Restatement on Financial Statements (Details) - USD ($)	3 Months Ended				4 Months Ended	6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 17,867,483				$ 17,867,483	$ 17,867,483		$ 27,265,703
Other receivables								6,987
Prepaid expenses and other current assets	1,990,049				1,990,049	1,990,049		434,699
Total current assets	19,857,532				19,857,532	19,857,532		27,707,389
Property and equipment, net	109,780				109,780	109,780		45,708
Operating lease right-of-use assets	385,361				385,361	385,361		477,882
Total assets	20,352,673				20,352,673	20,352,673		28,230,979
Current liabilities:
Accounts payable and accrued expenses	1,279,598				1,279,598	1,279,598		947,574
Short-term notes payable								303,416
Operating lease liabilities	180,824				180,824	180,824		194,270
Total current liabilities	1,460,422				1,460,422	1,460,422		1,445,260
Long-term liabilities:
Operating lease liabilities	217,353				217,353	217,353		299,520
Total long-term liabilities	217,353				217,353	217,353		299,520
Shareholders’ equity:
Preferred stock, no par value; 50,000,000 shares authorized; 9,417,000 Series A shares, 6,600,000 Series B shares, issued and outstanding at June 30, 2022 and December 31, 2021, respectively	2,656,713				2,656,713	2,656,713		2,656,713
Common stock, $0.001 par value; 250,000,000 and 200,000,000 shares authorized at June 30, 2022 and December 31, 2021, respectively, 116,394,806 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively	116,395				116,395	116,395		116,395
Additional paid-in capital	195,356,454				195,356,454	195,356,454		194,987,219
Accumulated deficit	(179,454,664)				(179,454,664)	(179,454,664)		(171,274,128)
Total shareholders’ equity	18,674,898	$ 21,985,453	$ 32,733,400	$ 36,050,467	18,674,898	18,674,898	$ 32,733,400	26,486,199	$ 16,844,595
Total liabilities and shareholders’ equity	20,352,673				20,352,673	20,352,673		$ 28,230,979
Grant revenue	30,391				30,391	45,474
Operating expenses:
Research and development	2,590,032		2,467,575		2,590,032	5,883,693	5,728,479
General and administrative	1,044,334		1,370,393		1,044,334	2,375,883	3,346,969
Total operating expenses	3,634,366		3,837,968		3,634,366	8,259,576	9,075,448
Loss from operations	(3,603,975)		(3,837,968)		(3,603,975)	(8,214,102)	(9,075,448)
Other income (expense):
Interest income	15,369		24,254		15,369	27,275	44,287
Interest expense	(816)		(1,033)		(816)	(4,062)	(3,601)
Local business tax	(490)		(600)		(490)	(980)	(1,200)
Miscellaneous income	369				369	11,333	670
Total other income, net	14,432		22,621		14,432	33,566	40,156
Loss before income taxes	(3,589,543)		(3,815,347)		(3,589,543)	(8,180,536)	(9,035,292)
Income tax benefit
Net loss	$ (3,589,543)	(4,590,993)	$ (3,815,347)	(5,219,945)	$ (3,589,543)	$ (8,180,536)	$ (9,035,292)
Basic and diluted net loss per share	$ (0.03)		$ (0.03)		$ (0.03)	$ (0.07)	$ (0.08)
Shares used to compute basic and diluted net loss per share	116,394,806		115,864,162		116,394,806	116,394,806	109,357,191
Cash flows from operating activities:
Net loss	$ (3,589,543)	(4,590,993)	$ (3,815,347)	$ (5,219,945)	$ (3,589,543)	$ (8,180,536)	$ (9,035,292)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization						18,847	25,176
Gain on sale of property and equipment						(10,964)
Stock-based compensation expense	278,988		$ 231,140			369,235	1,354,901
Changes in operating assets and liabilities:
Other receivables						6,987
Prepaid expenses and other current assets						(1,555,350)	256,189
Prepaid expenses and other current assets						1,555,350	(256,189)
Accounts payable and accrued expenses						332,024	993,251
Net cash used in operating activities						(9,019,757)	(6,405,775)
Cash flows from investing activities:
Proceeds from sale of property and equipment						12,000
Purchase of property and equipment						(87,047)
Net cash used in investing activities						(75,047)
Cash flows from financing activities:
Payments on short-term notes payable						(303,416)	(228,227)
Redemption of Series C Preferred stock							(5,635,672)
Proceeds from issuance of common stock for option exercise							267,140
Proceeds from issuance of common stock for warrant exercise							2,261,336
Net proceeds from issuance of common stock
Net cash provided by (used in) financing activities						(303,416)
Net increase (decrease) in cash and cash equivalents						(9,398,220)
Cash and cash equivalents at beginning of period		27,265,703				27,265,703
Cash and cash equivalents at end of period	17,867,483				17,867,483	17,867,483
Supplemental disclosure of cash flow information:
Interest paid						4,062	$ 3,601
Non-cash investing and financing activities:
Stock dividend on Series C Preferred stock
Previously Reported [Member]
Current assets:
Cash and cash equivalents	17,867,483				17,867,483	17,867,483
Other receivables
Prepaid expenses and other current assets	102,498				102,498	102,498
Total current assets	17,969,981				17,969,981	17,969,981
Property and equipment, net	109,780				109,780	109,780
Operating lease right-of-use assets	385,361				385,361	385,361
Total assets	18,465,122				18,465,122	18,465,122
Current liabilities:
Accounts payable and accrued expenses	1,279,598				1,279,598	1,279,598
Short-term notes payable
Operating lease liabilities	180,824				180,824	180,824
Total current liabilities	1,460,422				1,460,422	1,460,422
Long-term liabilities:
Operating lease liabilities	217,353				217,353	217,353
Total long-term liabilities	217,353				217,353	217,353
Shareholders’ equity:
Preferred stock, no par value; 50,000,000 shares authorized; 9,417,000 Series A shares, 6,600,000 Series B shares, issued and outstanding at June 30, 2022 and December 31, 2021, respectively	2,656,713				2,656,713	2,656,713
Common stock, $0.001 par value; 250,000,000 and 200,000,000 shares authorized at June 30, 2022 and December 31, 2021, respectively, 116,394,806 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively	116,395				116,395	116,395
Additional paid-in capital	195,356,454				195,356,454	195,356,454
Accumulated deficit	(181,342,215)				(181,342,215)	(181,342,215)
Total shareholders’ equity	16,787,347				16,787,347	16,787,347
Total liabilities and shareholders’ equity	18,465,122				18,465,122	18,465,122
Grant revenue					30,391	45,474
Operating expenses:
Research and development					3,033,182	7,771,244
General and administrative					1,044,334	2,375,883
Total operating expenses					4,077,516	10,147,127
Loss from operations					(4,047,125)	(10,101,653)
Other income (expense):
Interest income					15,369	27,275
Interest expense					(816)	(4,062)
Local business tax					(490)	(980)
Miscellaneous income					369	11,333
Total other income, net					14,432	33,566
Loss before income taxes					(4,032,693)	(10,068,087)
Income tax benefit
Net loss	4,000,000				$ (4,032,693)	$ (10,068,087)
Basic and diluted net loss per share					$ (0.03)	$ (0.09)
Shares used to compute basic and diluted net loss per share					116,394,806	116,394,806
Cash flows from operating activities:
Net loss	4,000,000				$ (4,032,693)	$ (10,068,087)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization						18,847
Gain on sale of property and equipment						(10,964)
Stock-based compensation expense						369,235
Changes in operating assets and liabilities:
Other receivables						6,987
Prepaid expenses and other current assets						332,201
Prepaid expenses and other current assets						(332,201)
Accounts payable and accrued expenses						332,024
Net cash used in operating activities						(9,019,757)
Cash flows from investing activities:
Proceeds from sale of property and equipment						12,000
Purchase of property and equipment						(87,047)
Net cash used in investing activities						(75,047)
Cash flows from financing activities:
Payments on short-term notes payable						(303,416)
Redemption of Series C Preferred stock
Proceeds from issuance of common stock for option exercise
Proceeds from issuance of common stock for warrant exercise
Net proceeds from issuance of common stock
Net cash provided by (used in) financing activities						(303,416)
Net increase (decrease) in cash and cash equivalents						(9,398,220)
Cash and cash equivalents at beginning of period		$ 27,265,703				27,265,703
Cash and cash equivalents at end of period	17,867,483				17,867,483	17,867,483
Supplemental disclosure of cash flow information:
Interest paid						4,062
Non-cash investing and financing activities:
Stock dividend on Series C Preferred stock
Revision of Prior Period, Adjustment [Member]
Current assets:
Prepaid expenses and other current assets	1,887,551				1,887,551	1,887,551
Shareholders’ equity:
Accumulated deficit	$ 1,887,551				1,887,551	1,887,551
Operating expenses:
Research and development					$ (443,150)	(1,887,551)
Other income (expense):
Net loss						1,887,551
Cash flows from operating activities:
Net loss						1,887,551
Changes in operating assets and liabilities:
Prepaid expenses and other current assets						1,887,551
Prepaid expenses and other current assets						$ (1,887,551)

Schedule of Effect of Restate_2

Schedule of Effect of Restatement on Financial Statements (Details) (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Preferred stock, no par value	$ 0	$ 0
Preferred stock, shares authorized	50,000,000	50,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	200,000,000
Common stock, shares issued	116,394,806	116,394,806
Common stock, shares outstanding	116,394,806	116,394,806
Series A Preferred Stock [Member]
Preferred stock, shares issued	9,417,000	9,417,000
Preferred stock, shares outstanding	9,417,000	9,417,000
Series B Preferred Stock [Member]
Preferred stock, shares issued	6,600,000	6,600,000
Preferred stock, shares outstanding	6,600,000	6,600,000

Organization (Details Narrative

Organization (Details Narrative) - USD ($)	3 Months Ended				4 Months Ended	6 Months Ended
Organization (Details Narrative) - USD ($)	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net Income (Loss) Attributable to Parent	$ (3,589,543)	$ (4,590,993)	$ (3,815,347)	$ (5,219,945)	$ (3,589,543)	$ (8,180,536)	$ (9,035,292)
Assets	20,352,673				20,352,673	20,352,673		$ 28,230,979
Retained Earnings (Accumulated Deficit)	(179,454,664)				(179,454,664)	(179,454,664)		(171,274,128)
Net Income (Loss) Attributable to Parent	3,589,543	4,590,993	$ 3,815,347	$ 5,219,945	3,589,543	8,180,536	$ 9,035,292
Retained Earnings (Accumulated Deficit)	179,454,664				179,454,664	179,454,664		$ 171,274,128
Revision of Prior Period, Change in Accounting Principle, Adjustment [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net Income (Loss) Attributable to Parent	400,000					1,900,000
Assets	1,900,000				1,900,000	1,900,000
Retained Earnings (Accumulated Deficit)	1,900,000				1,900,000	1,900,000
Net Income (Loss) Attributable to Parent	(400,000)					(1,900,000)
Retained Earnings (Accumulated Deficit)	(1,900,000)				(1,900,000)	(1,900,000)
Previously Reported [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net Income (Loss) Attributable to Parent	4,000,000				(4,032,693)	(10,068,087)
Assets	18,465,122				18,465,122	18,465,122
Retained Earnings (Accumulated Deficit)	(181,342,215)				(181,342,215)	(181,342,215)
Net Income (Loss) Attributable to Parent	(4,000,000)				4,032,693	10,068,087
Retained Earnings (Accumulated Deficit)	181,342,215				181,342,215	181,342,215
Previously Reported [Member] \| Versus [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Retained Earnings (Accumulated Deficit)		18,000,000
Retained Earnings (Accumulated Deficit)		$ (18,000,000)
Revision of Prior Period, Accounting Standards Update, Adjustment [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Retained Earnings (Accumulated Deficit)	181,000,000				181,000,000	181,000,000
Retained Earnings (Accumulated Deficit)	$ (181,000,000)				$ (181,000,000)	$ (181,000,000)

Basis of Presentation, As Res_2

Basis of Presentation, As Restated (Details Narrative) - USD ($)	3 Months Ended				4 Months Ended	6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Accounting Policies [Abstract]
Net loss	$ 3,589,543	$ 4,590,993	$ 3,815,347	$ 5,219,945	$ 3,589,543	$ 8,180,536	$ 9,035,292
Cash used in operations						9,019,757	$ 6,405,775
Accumulated deficit	$ 179,454,664				$ 179,454,664	$ 179,454,664		$ 171,274,128

Significant Accounting Polici_3

Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		4 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Product Information [Line Items]
Uninsured portion of balance	$ 17,617,483		$ 17,617,483	$ 17,617,483		$ 27,015,703
Revenue	$ 30,391		$ 30,391	45,474
Grant [Member]
Product Information [Line Items]
Revenue				$ 250,000

Schedule of Stock Based Compens

Schedule of Stock Based Compensation Expenses Recognized (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total Stock-based compensation	$ 278,988	$ 231,140	$ 369,235	$ 1,354,901
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total Stock-based compensation	26,399	48,761	65,854	79,688
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total Stock-based compensation	$ 252,589	$ 182,379	$ 303,381	$ 1,275,213

Summary of Stock Option Activit

Summary of Stock Option Activity (Details) - USD ($)		6 Months Ended	12 Months Ended
Summary of Stock Option Activity (Details) - USD ($)		Jun. 30, 2022	Dec. 31, 2021
Share-Based Payment Arrangement [Abstract]
Number of options, outstanding, beginning balance		6,724,402
Weighted average exercise price, beginning balance		$ 0.95
Weighted average contractual term		8 years 21 days	7 years 11 months 26 days
Aggregate Intrinsic value outstanding, beginning	[1]	$ 2,773
Number of options, outstanding, Granted		1,382,500
Weighted average exercise price, Granted		$ 0.32
Number of options, outstanding, Exercised
Weighted average exercise price, Exercised
Number of options, outstanding, Expired		(4,500)
Weighted average exercise price, Expired		$ 12
Number of options, outstanding, Forfeited		(726,998)
Weighted average exercise price, Forfeited		$ 0.94
Number of options, outstanding, Ending Balance		7,375,404	6,724,402
Weighted average exercise price, Ending Balance		$ 0.83	$ 0.95
Aggregate Intrinsic value outstanding, ending	[1]	$ 72,050	$ 2,773
Number of options, outstanding, Exercisable Ending Balance		5,952,900
Weighted average exercise price, Exercisable Ending Balance		$ 0.89
Weighted average contractual term, exercisable		7 years 8 months 26 days
Aggregate Intrinsic value Exercisable, Ending	[1]	$ 36,300

[1]The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock option awards and the closing market price of our common stock as of December 31, 2021 and June, 2022, respectively.

Stock-based Compensation (Detai

Stock-based Compensation (Details Narrative) - USD ($)		6 Months Ended
Stock-based Compensation (Details Narrative) - USD ($)	Feb. 25, 2022	Jun. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized compensation cost related to unvested stock options		$ 436,162
Weighted average period		2 years
Non Employee Directors [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Annual retainer amount for the threshold of stock precluded from selling		$ (270,000)
2021 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Issuance of stock, shares	10,000,000
Reserved for future issuance		9,877,306

Schedule of Warrants Activity (

Schedule of Warrants Activity (Details) - $ / shares	6 Months Ended	12 Months Ended
Schedule of Warrants Activity (Details) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Warrants
Warrants, beginning balance	18,040,572	20,513,145
Weighted average price, beginning balance	$ 1.42	$ 1.36
Warrants, Granted
Weighted average price, Granted
Warrants, Exercised		(2,472,573)
Weighted average price, Exercised		$ 0.91
Warrants, Expired
Weighted average price, Expired
Warrants, ending balance	18,040,572	18,040,572
Weighted average price ending balance	$ 1.42	$ 1.42

Schedule of Warrants Outstandin

Schedule of Warrants Outstanding (Details)	Jun. 30, 2022 $ / shares shares
Class of Warrant or Right [Line Items]
Warrants Outstanding	18,040,572
Range One [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding Exercise Price \| $ / shares	$ 3.10
Warrants Outstanding	48,387
Expiration Date	Sep. 19, 2022
Range Two [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding Exercise Price \| $ / shares	$ 2
Warrants Outstanding	900,000
Expiration Date	Apr. 10, 2023
Range Three [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding Exercise Price \| $ / shares	$ 3.10
Warrants Outstanding	462,106
Expiration Date	May 10, 2024
Range Four [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding Exercise Price \| $ / shares	$ 3.10
Warrants Outstanding	602,414
Expiration Date	Jul. 25, 2024
Range Five [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding Exercise Price \| $ / shares	$ 3.10
Warrants Outstanding	1,064,518
Expiration Date	Nov. 08, 2024
Range Six [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding Exercise Price \| $ / shares	$ 1
Warrants Outstanding	3,174,500
Expiration Date	Jul. 17, 2025
Range Seven [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding Exercise Price \| $ / shares	$ 0.90
Warrants Outstanding	2,588,647
Expiration Date	Mar. 25, 2024
Range Eight [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding Exercise Price \| $ / shares	$ 1.25
Warrants Outstanding	9,200,000
Expiration Date	May 01, 2025

Warrants (Details Narrative)

Warrants (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended
Warrants (Details Narrative) - USD ($)	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Proceeds from warrant exercises			$ 2,261,336
Warrant [Member]
Number of common stock issued in offering	2,472,573
Proceeds from warrant exercises	$ 2,261,336
Warrant One [Member]
Warrants to purchase shares of common stock	360,000
Warrants exercise price per share	$ 1
Warrant Two [Member]
Warrants to purchase shares of common stock	2,112,573
Warrants exercise price per share	$ 0.90

Schedule of Prepaids (Details)

Schedule of Prepaids (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Prepaids As Restated
Prepaid Expense	$ 1,972,109	$ 416,759
Deposits	17,940	17,940
Total	$ 1,990,049	$ 434,699

Prepaids, As Restated (Details

Prepaids, As Restated (Details Narrative) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Unusual or Infrequent Item, or Both [Line Items]
Prepaid expense and other current assets	$ 1,990,049	$ 434,699
Prepaid insurance	80,000
Deposits	17,940	17,940
Research and Development Expense [Member]
Unusual or Infrequent Item, or Both [Line Items]
Prepaid insurance	1,900,000
Covid 19 [Member]
Unusual or Infrequent Item, or Both [Line Items]
Prepaid expense and other current assets	$ 1,990,049	$ 434,699

Short-Term Notes Payable (Detai

Short-Term Notes Payable (Details Narrative) - USD ($)	Jul. 24, 2021	Jul. 24, 2020	Jun. 30, 2022	Dec. 31, 2021
Short-Term Debt [Line Items]
Short-term notes payable				$ 303,416
Short-term Note Payable [Member] \| Directors' and Officers' Insurance [Member]
Short-Term Debt [Line Items]
Short-term notes payable	$ 600,169	$ 413,784
Debt interest rate	5.34%	5.39%
Amortization period	10-month	11-month
Debt maturity date	May 16, 2022	Jun. 28, 2021

Schedule of Supplemental Balanc

Schedule of Supplemental Balance Sheet Information Related to Leases (Details)	Jun. 30, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Weighted average remaining lease term in years, operating leases	1 year 11 months 12 days	2 years 5 months 12 days
Weighted average discount rate, operating leases	5.69%	5.70%

Schedule of Maturities of Opera

Schedule of Maturities of Operating Lease Liabilities (Details)	Dec. 31, 2021 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2022	$ 108,829
2023	169,656
2024	146,718
Total	425,203
Less: Imputed interest	(27,026)
Present value of lease liabilities	$ 398,177

Schedule of Cost Component of O

Schedule of Cost Component of Operating Leases (Details) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Operating lease cost	$ 114,259	$ 114,002
Short-term lease cost	1,965	782
Total lease cost	$ 116,224	$ 114,784

Schedule of Supplemental Cash F

Schedule of Supplemental Cash Flow Information Related to Operating Leases (Details) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases	$ 117,350	$ 113,454

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative)	1 Months Ended			3 Months Ended		6 Months Ended		12 Months Ended
Commitments and Contingencies (Details Narrative)	May 31, 2020 $ / shares	Nov. 30, 2019 USD ($)	Nov. 30, 2016 USD ($) ft²	Mar. 31, 2022 USD ($)	Mar. 31, 2021 $ / shares shares	Jun. 30, 2022 USD ($) $ / shares	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Loss Contingencies [Line Items]
Monthly lease payments \| $						$ 117,350	$ 113,454
Tampa Facility [Member]
Loss Contingencies [Line Items]
Area of office space leased \| ft²			2,207
Lease description		the Company entered into an amendment for the Tampa facility for a term of three years beginning in March of 2020.	The lease period for the office space is for thirty-six months commencing on March 1, 2017.
Lease expiration date			Feb. 29, 2020
Range One [Member]
Loss Contingencies [Line Items]
Warrants exercise price per share \| $ / shares						$ 3.10
Range Two [Member]
Loss Contingencies [Line Items]
Warrants exercise price per share \| $ / shares						$ 2
Minimum [Member] \| Alachua Facility [Member]
Loss Contingencies [Line Items]
Payments of rent \| $						$ 12,870
Minimum [Member] \| Tampa Facility [Member]
Loss Contingencies [Line Items]
Monthly lease payments \| $		$ 4,524	$ 4,138
Maximum [Member] \| Tampa Facility [Member]
Loss Contingencies [Line Items]
Monthly lease payments \| $		$ 4,800	$ 4,392
Warrant [Member]
Loss Contingencies [Line Items]
Exercise of warrants \| shares					2,472,573
Warrant [Member] \| Range One [Member]
Loss Contingencies [Line Items]
Warrants exercise price per share \| $ / shares					$ 1
Exercise of warrants \| shares					360,000
Warrant [Member] \| Range Two [Member]
Loss Contingencies [Line Items]
Warrants exercise price per share \| $ / shares					$ 0.90
Exercise of warrants \| shares					2,112,573
Warrant One [Member]
Loss Contingencies [Line Items]
Warrants exercise price per share \| $ / shares					$ 1
Noachis Terra, Inc. [Member] \| Warrant [Member]
Loss Contingencies [Line Items]
Operating activities \| $								$ 542,263
Stock Purchase Agreement [Member] \| Warrant [Member] \| Mr. Joseph Hernandez [Member] \| Minimum [Member]
Loss Contingencies [Line Items]
Warrants exercise price per share \| $ / shares	$ 0.75
Stock Purchase Agreement [Member] \| Warrant [Member] \| Mr. Joseph Hernandez [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Warrants exercise price per share \| $ / shares	$ 0.90
Stock Purchase Agreement [Member] \| Warrant One [Member] \| Mr. Joseph Hernandez [Member]
Loss Contingencies [Line Items]
Percentage of warrant exercise	45%
Warrants exercise price per share \| $ / shares	$ 1
Stock Purchase Agreement [Member] \| Noachis Terra, Inc. [Member] \| Warrant [Member]
Loss Contingencies [Line Items]
Contingent consideration descriptions	(i) twenty percent (20%) of the cash proceeds received by the Company upon exercise of the Company’s warrants carrying an exercise price of $0.75 and $0.90 and (ii) forty-five percent (45%) of the cash proceeds received by the Company upon exercise of the Company’s warrants carrying an exercise price of $1.00, in each case, for so long as the warrants remain outstanding.
Percentage of warrant exercise	20%
Warrants exercise term description	The Company’s previously issued warrants carrying an exercise price of $0.75 have expired by their terms. As a result, no additional consideration will be due to the former sole shareholder of NTI relating to these warrants.
License Agreement [Member]
Loss Contingencies [Line Items]
Royalty expenses \| $				$ 30,000
Reimbursement expenses \| $				$ 11,739
Agreement expiration term				20 years
Alachua Facility [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Payments of rent \| $						$ 13,338

Shareholders_ Equity (Details N

Shareholders’ Equity (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended
Shareholders’ Equity (Details Narrative) - USD ($)	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Feb. 25, 2022	Dec. 31, 2021	Mar. 15, 2021	Jan. 28, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock shares authorized		250,000,000			200,000,000
Gross proceeds from common stock			$ 26,676,392
Warrants outstanding		18,040,572
Series C Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Redemption of preferred shares							26.697
Redemption of preferred stock						$ 5,600,000
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock shares authorized		250,000,000		200,000,000
Number of shares issued during the period	23,871,338
Warrants outstanding	2,472,573
Gross proceeds from warrants	$ 2,300,000
Common Stock [Member] \| ATM Program [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued during the period	21,398,765
Gross proceeds from common stock	$ 27,800,000